파종성 혈관 내 응고(DIC) 시장 : 인사이트, 역학, 예측(-2034년)

Key Highlights:

• In Disseminated Intravascular Coagulation (DIC), excessive fibrin deposition blocks small vessels, disrupting microcirculation and causing ischemic injury in organs like kidneys and lungs, which often progresses to organ failure from impaired blood flow and oxygen delivery.
• Secondary data analysis from the US indicates that DIC occurs at an incidence of 18.6 cases per 100,000 individuals, underscoring its relatively uncommon yet clinically significant presence, particularly as a complication of critical conditions such as sepsis, trauma, and malignancies.
• The rising incidence of DIC is driven by increased cases of sepsis, trauma, malignancies, and obstetric complications. Advances in critical care have improved survival, but also exposed more patients to conditions that trigger DIC. Enhanced diagnostic awareness and monitoring further contribute to higher detection rates in hospitalized and critically ill populations.
• A major challenge in DIC is the limited availability of robust epidemiological data, hindering accurate assessment of its true incidence and outcomes across populations, which restricts effective healthcare planning, timely diagnosis, and development of targeted therapeutic strategies.
• The treatment for DIC remains limited across the seven major markets, with a significant need for approved targeted therapies. RECOMODULIN (thrombomodulin alfa), a recombinant thrombomodulin, is currently approved only in Japan for DIC management. Elsewhere, treatment relies primarily on supportive anticoagulant therapies, highlighting the global gap in mechanism-based interventions that address both coagulation and inflammation.

DelveInsight's comprehensive report titled "Disseminated Intravascular Coagulation (DIC) - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of DIC. The report presents historical and projected epidemiological data covering incident cases of DIC, gender-specific incident cases of DIC, comorbidity-specific incident cases of DIC, treated cases of DIC. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across 7MM: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in DIC. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Disseminated Intravascular Coagulation (DIC) Overview

DIC is a serious condition marked by widespread activation of the clotting cascade, resulting in the formation of clots throughout the small and large blood vessels. This abnormal clotting disrupts normal blood flow and can lead to multiple organ dysfunction. As clotting factors and platelets are consumed in this process, the body may paradoxically begin to bleed-sometimes presenting as the first symptom of DIC. DIC often arises acutely in individuals with critical underlying conditions such as severe infections (especially sepsis), hematologic cancers, major trauma, or obstetric complications like placental abruption. Assessing the impact and mortality of DIC is challenging because affected patients frequently have other serious illnesses that mimic or exacerbate DIC symptoms-particularly liver failure. However, studies show that the presence of DIC in septic or severely injured patients significantly increases the risk of death.

The condition is typically triggered by a systemic inflammatory response or the release of procoagulant substances into the bloodstream. While gram-negative bacterial infections are commonly linked to DIC, gram-positive organisms and even parasitic infections can also initiate the disorder.

Disseminated Intravascular Coagulation (DIC) Diagnosis and Treatment Overview

Diagnosing DIC requires a combination of clinical assessment and laboratory findings, as no single test is definitive. Key lab indicators include prolonged prothrombin time and Activated Partial Thromboplastin Time (aPTT), low fibrinogen, thrombocytopenia, reduced hematocrit, and schistocytes on peripheral smear. Elevated fibrin split products (e.g., D-dimer) are sensitive but not specific. The 2007 DIC scoring system based on platelet count, PT, fibrinogen, and fibrin markers helps identify overt DIC, with scores >5 indicating high likelihood.

Treatment focuses on managing the underlying cause, such as antibiotics for sepsis, delivery in placental abruption, or surgery for trauma. Supportive care includes transfusions only for patients with active bleeding, high bleeding risk, or those undergoing invasive procedures. Platelet transfusion thresholds are <50 X 109/L for bleeding patients and 10-20 X 109/L for high-risk but non-bleeding individuals. Prompt recognition and targeted therapy are essential to reduce morbidity and mortality.

Disseminated Intravascular Coagulation (DIC) Epidemiology

The epidemiology section of the DIC market report offers information on the patient populations, including historical and projected trends for each of the 7MM. Examining Key Opinion Leader (KOL) views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of DIC. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• A study conducted in Japan revealed that the initial incidence of DIC at the time of hospital admission was relatively low, at 1.1%. However, when patients were monitored longitudinally and assessed for DIC on days 1, 4, 8, and 15 post-admission, the cumulative incidence rose significantly to 10.9%.
• Secondary data analysis from the US indicates that DIC incidence shows a slightly higher incidence in males (52.73%) compared to females (47.27%), suggesting a modest gender imbalance in disease occurrence.
• Secondary analysis from Germany indicates that nearly 40% of DIC cases were attributable to sepsis, highlighting sepsis as the most significant driver of DIC burden in that population compared to other underlying triggers.
• Based on the secondary analysis in Japan, despite its severity, DIC affects an estimated 1% of all hospitalized patients, indicating that while relatively uncommon overall, it remains a critical concern in specific high-risk populations.

Disseminated Intravascular Coagulation (DIC) Market Outlook

The DIC therapeutics market is further expected to increase by the major drivers, such as the rising incident population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

The treatment landscape for DIC remains largely supportive, with a primary focus on managing the underlying condition such as sepsis, trauma, malignancy, or obstetric complications that triggers the coagulation cascade. Standard care includes transfusions of platelets and plasma to control bleeding and maintain hemostatic balance, especially in patients undergoing invasive procedures or experiencing active hemorrhage. Anticoagulants like heparin may be cautiously used in cases dominated by thrombosis, though bleeding risk limits their application.

Currently, RECOMODULIN (thrombomodulin alfa) is the only approved targeted therapy for DIC, and it is available exclusively in Japan. It offers dual anticoagulant and anti-inflammatory effects by activating protein C and inhibiting thrombin generation. Outside Japan, no specific DIC therapies are approved, underscoring a significant unmet need. The global market relies on off-label anticoagulants and supportive care.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the DIC market in the 7MM is expected to change significantly during the forecast period (2025-2034).

Disseminated Intravascular Coagulation (DIC) Drug Chapters

Marketed Drugs

RECOMODULIN (thrombomodulin alfa): Asahi Kasei Pharma

RECOMODULIN, developed by Asahi Kasei, is a recombinant thrombomodulin used to treat DIC. It binds thrombin to activate protein C, which inhibits coagulation factors Va and VIIIa, reducing thrombin production and abnormal clotting. Additionally, RECOMODULIN helps mitigate inflammation and microvascular thrombosis, offering both anticoagulant and anti-inflammatory benefits in managing DIC.

• RECOMODULIN received regulatory approval in Japan in January 2008, marking a significant advancement in the therapeutic management of disseminated intravascular coagulation.

Disseminated Intravascular Coagulation (DIC) Market Segmentation

DelveInsight's 'Disseminated Intravascular Coagulation (DIC) - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future DIC market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Disseminated Intravascular Coagulation (DIC) Market Size by Countries

The DIC market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2024, the United States held a significant share of the overall 7MM DIC market, primarily attributed to the country's higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Disseminated Intravascular Coagulation (DIC) Drugs Uptake

This section focuses on the sales uptake of potential DIC drugs that have recently been launched or are anticipated to be launched in the DIC market between 2020 and 2034. It estimates the market penetration of DIC drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the DIC market.

The emerging DIC therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the DIC market.

Disseminated Intravascular Coagulation (DIC) Market Access and Reimbursement

DelveInsight's 'Disseminated Intravascular Coagulation (DIC) - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of DIC. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Key Opinion Leader (KOL) Views

To keep up with current DIC market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the DIC domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or DIC market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the DIC unmet needs.

Disseminated Intravascular Coagulation (DIC): KOL Insights

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, Creighton University School of Medicine, US, University Medical Center Greifswald, Greifswald, Germany; Universite Paris Descartes, Paris, France, France; University GD'Annunzio Foundation, Chieti,, Italy; Royal Liverpool University Hospital, Liverpool, UK; University School of Medicine, Mie, Japan, among others.

"As per KOL from the US, "DIC is increasingly recognized not merely as a complication but as a critical prognostic indicator in conditions like sepsis and trauma. Its presence signals heightened disease severity and risk of poor outcomes, prompting the need for vigilant monitoring, early identification, and timely intervention to improve survival and reduce complications."

"As per KOL from the UK, "DIC lacks targeted therapies that effectively balance anticoagulation with bleeding risk. Current treatments focus on supportive care and underlying causes, leaving a gap in direct intervention. Rapid diagnosis and safer, mechanism-based therapies are urgently needed to reduce morbidity and mortality in critically ill patients with DIC."

"As per KOL from Japan, "Accurate diagnosis of DIC requires careful differentiation from other hematologic disorders with overlapping features. Conditions such as dysfibrinogenemia, hemolytic uremic syndrome, heparin-induced thrombocytopenia, immune thrombocytopenia, and thrombotic thrombocytopenic purpura must be considered. Misdiagnosis can lead to inappropriate treatment, underscoring the need for comprehensive clinical and laboratory evaluation."

Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the DIC. Market, utilizing various competitive intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Disseminated Intravascular Coagulation (DIC) Pipeline Development Activities

The report offers an analysis of therapeutic candidates in early and late stage molecule and examines companies involved in developing targeted therapeutics for DIC. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging DIC therapies.

Disseminated Intravascular Coagulation (DIC) Report Insights

• DIC Patient Population
• Therapeutic Approaches
• DIC Pipeline Analysis
• DIC Market Size and Trends
• DIC Market Opportunities
• Impact of Upcoming Therapies

Disseminated Intravascular Coagulation (DIC) Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• DIC Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed DIC Market
• DIC Drugs Uptake

Disseminated Intravascular Coagulation (DIC) Report Assessment

• DIC Current Treatment Practices
• Unmet Needs
• DIC Product Profiles
• DIC Market Attractiveness

Key Questions:

• How common is DIC?
• What are the key findings of DIC epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for DIC?
• What are the disease risk, burden, and unmet needs of DIC?
• At what CAGR is the DIC market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the DIC market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of DIC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of DIC?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the DIC market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of market access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of KOL around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for DIC?

The primary treatment goals for DIC are to address the underlying cause, restore hemostatic balance, and prevent organ damage. This involves controlling the triggering condition (e.g., infection, trauma), supporting coagulation with transfusions when necessary, and minimizing both thrombosis and bleeding risks. Timely intervention, close monitoring, and individualized care are essential to reduce morbidity and improve patient outcomes in this complex and dynamic disorder.

2. What are the challenges in managing DIC?

Managing DIC presents several challenges, including its complex pathophysiology, variable clinical presentation, and overlap with other critical conditions. Balancing anticoagulation with bleeding risk is difficult, especially in unstable patients. Diagnostic limitations and lack of targeted therapies further complicate care. Rapid progression and multi-organ involvement demand timely, multidisciplinary intervention, yet treatment often remains supportive. These factors contribute to high morbidity and mortality, underscoring the need for improved diagnostic and therapeutic strategies.

3. What are the key factors driving the growth of the DIC market?

Key factors driving growth in the DIC market include rising incidence of sepsis, trauma, and cancer-related coagulopathies, which increase DIC incidence. Advancements in diagnostic tools and scoring systems enhance early detection. Growing awareness among clinicians and demand for targeted therapies, such as recombinant thrombomodulin and novel anticoagulants, also fuel market expansion. Additionally, ongoing clinical research and regulatory support for innovative treatments contribute to the market's evolving landscape.

4. How will the DIC market and epidemiology forecast report benefit the clients?

The DIC market and epidemiology forecast report offers clients strategic insights into disease incidence, patient segmentation, and market dynamics. It helps identify commercial opportunities, assess treatment gaps, and support planning for product development, market entry, or expansion. The report also aids stakeholders in understanding regulatory landscapes, forecasting trends, and making data-driven investment or policy decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. DIC Market Overview at a Glance

• 3.1. Market Share (%) Distribution of DIC by Therapies in the 7MM in 2024
• 3.2. Market Share (%) Distribution of DIC by Therapies in the 7MM in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale:7MM
• 8.3. Incident Cases of DIC in the 7MM
• 8.4. The United States
  • 8.4.1. Incident Cases of DIC
  • 8.4.2. Gender-specific Incident Cases of DIC
  • 8.4.3. Comorbidity-specific Incident Cases of DIC
  • 8.4.4. Treated Cases of DIC
• 8.5. EU4 and the UK
  • 8.5.1. Incident Cases of DIC
  • 8.5.2. Gender-specific Incident Cases of DIC
  • 8.5.3. Comorbidity-specific Incident Cases of DIC
  • 8.5.4. Treated Cases of DIC
• 8.6. Japan
  • 8.6.1. Incident Cases of DIC
  • 8.6.2. Gender-specific Incident Cases of DIC
  • 8.6.3. Comorbidity-specific Incident Cases of DIC
  • 8.6.4. Treated Cases of DIC

9. Patient Journey

10. Marketed Therapies

• 10.1. RECOMODULIN (thrombomodulin alfa): Asahi Kasei Pharma
  • 10.1.1. Product Description
  • 10.1.2. Regulatory Milestones
  • 10.1.3. Other Development Activities
  • 10.1.4. Clinical Trials Information
  • 10.1.5. Safety and Efficacy

11. DIC: Major Market Analysis

• 11.1. Key Findings
• 11.2. Market Outlook
• 11.3. Attribute Analysis
• 11.4. Key Market Forecast Assumptions
  • 11.4.1. Cost Assumptions and Rebates
  • 11.4.2. Pricing Trends
  • 11.4.3. Analogue Assessment
  • 11.4.4. Launch Year and Therapy Uptake
• 11.5. Total Market Size of DIC in the 7MM
• 11.6. Market Size of DIC by Therapies in the 7MM
• 11.7. The United States Market Size
  • 11.7.1. Total Market Size of DIC
  • 11.7.2. Market Size of DIC by Therapies
• 11.8. EU4 and the UK Market Size
  • 11.8.1. Total Market Size of DIC
  • 11.8.2. Market Size of DIC by Therapies
• 11.9. Japan Market Size
  • 11.9.1. Total Market Size of DIC
  • 11.9.2. Market Size of DIC by Therapies

12. Key Opinion Leaders' Views

13. Unmet Needs

14. SWOT Analysis

15. Market Access and Reimbursement

16. Appendix

• 16.1. Bibliography
• 16.2. Abbreviations and Acronyms
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight